Compare TGTX & SOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | SOLS |
|---|---|---|
| Founded | 1993 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.2B |
| IPO Year | 2008 | 2025 |
| Metric | TGTX | SOLS |
|---|---|---|
| Price | $64.36 | $64.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $69.43 | ★ $77.90 |
| AVG Volume (30 Days) | 1.8M | ★ 2.5M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.47% |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | 0.52 | ★ 1.78 |
| Revenue | $2,785,000.00 | ★ $3,886,000,000.00 |
| Revenue This Year | $61.95 | $8.36 |
| Revenue Next Year | $35.55 | $5.95 |
| P/E Ratio | $120.60 | ★ $35.86 |
| Revenue Growth | N/A | ★ 3.08 |
| 52 Week Low | $26.76 | $42.77 |
| 52 Week High | $68.03 | $90.80 |
| Indicator | TGTX | SOLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 54.61 |
| Support Level | $52.12 | $55.64 |
| Resistance Level | $63.60 | $65.33 |
| Average True Range (ATR) | 3.52 | 2.86 |
| MACD | 0.14 | 0.31 |
| Stochastic Oscillator | 64.62 | 72.16 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.